A phase 3 study of the COVID-19 vaccine reported an overall 90.4% efficacy. A study of 29,960 patients also found that the vaccine provided 100% protection against moderate to severe illness. The company plans to apply for regulatory approval in the third quarter and will reach production capacity of 100 million times a month by the end of the third quarter and 150 million times a month by the end of the fourth quarter. Stated. Shares in the Gaithersburg, Maryland company surged 8% in pre-marketing transactions.
Novavax reports that the COVID-19 vaccine was 90% effective in a phase 3 trial
Source link Novavax reports that the COVID-19 vaccine was 90% effective in a phase 3 trial